Africa Business Radio

Moderna says giving a full dose of Moderna’s Covid-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections. Moderna says preliminary data show antibody response to Omicron at the 50 microgram dose increased 37-fold but when the dose was doubled, antibody levels increased 83-fold. Moderna CEO Stephane Bancel called the results reassuring adding that the company is continuing to develop an Omicron-specific jab. The statement says clinical trials for a targeted vaccine are likely to begin in early 2022.